BWBradley Watmuff

Bradley Watmuff

*This is an algorithmically generated author record based on publicly available information.

Bradley Watmuff has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Drug treatment alters performance in a neural microphysiological system of information processing

    by Bradley Watmuff, Forough Habibollahi, Candice Desouza, Moein Khajehnejad, Alon Loeffler, Koby Baranes, Noah Poulin, Mark Kotter, Brett J. Kagan

    Assessment of pharmacological intervention on in vitro neural systems often emphasizes molecular and structural changes. However, neural systems fundamentally process and act on information. For preclinical assays to predict drug efficacy, they must model these physiological functions. DishBrain, an in vitro synthetic biological intelligence (SBI) assay embodying a neural system in a simulated game-world, enables the quantification of this information-processing capacity, however the question remains whether such a system permits classical pharmacological interrogation and dose-response profiling. Hyperactive glutamatergic dysregulation is linked to neurological disorders including epilepsy, and inducible overexpression of neurogenin 2 (NGN2) in human induced pluripotent stem cells (hiPSCs) generates glutamatergic cultures with dysregulated hyperactivity. We therefore tested three anti-seizure medications (ASMs), phenytoin, perampanel, and carbamazepine, on NGN2 neurons from day 21 of differentiation in this system. The key finding was that, while all compounds altered spontaneous firing, carbamazepine 200 µM significantly improved gameplay metrics. This marks the first demonstration of altered SBI following exogenous drug treatment. Notably, only inhibitory compounds enhanced goal-directed activity, linking glutamatergic attenuation to performance. Neurocomputational analysis revealed nuanced pharmacological responses during closed-loop stimulation, highlighting insights beyond spontaneous activity metrics.


  • Open Access

    Harnessing Intelligence from Brain Cells In Vitro

    by Brett J. Kagan, Forough Habibollahi, Brad Watmuff, Azin Azadi, Finn Doensen, Alon Loeffler, Seung Hoon Byun, Bram Servais, Candice Desouza, Kwaku Dad Abu-Bonsrah, et al.

    Harnessing intelligence from brain cells in vitro requires a multidisciplinary approach integrating wetware, hardware, and software. Wetware comprises the in vitro brain cells themselves, where differentiation from induced pluripotent stem cells offers ethical scalability; hardware typically involves a life support system and a setup to record the activity from and deliver stimulation to the brain cells; and software is required to control the hardware and process the signals coming from and going to the brain cells. This review provides a broad summary of the foundational technologies underpinning these components, along with outlining the importance of technology integration. Of particular importance is that this new technology offers the ability to extend beyond traditional methods that assess primarily the survival and spontaneous activity of neural cultures. Instead, the focus returns to the core function of neural tissue: the neurocomputational ability to process information and respond accordingly. Therefore, this review also covers work that, despite the relatively early state of current technology, has provided novel and meaningful understandings in the field of neuroscience along with opening exciting avenues for future research.


  • Open Access

    Drug treatment alters performance in a neural microphysiological system of information processing

    by Bradley Watmuff, Forough Habibollahi, Candice Desouza, Moein Khajehnejad, Alon Loeffler, Koby Baranes, Noah Poulin, Mark Kotter, Brett J. Kagan

    Assessment of pharmacological intervention on in vitro neural systems often emphasizes molecular and structural changes. However, neural systems fundamentally process and act on information. For preclinical assays to predict drug efficacy, they must model these physiological functions. DishBrain , an in vitro synthetic biological intelligence (SBI) assay embodying a neural system in a simulated game-world, enables the quantification of this information-processing capacity, however the question remains whether such a system permits classical pharmacological interrogation and dose-response profiling. Hyperactive glutamatergic dysregulation is linked to neurological disorders including epilepsy, and inducible overexpression of neurogenin 2 (NGN2) in human induced pluripotent stem cells (hiPSCs) generates glutamatergic cultures with dysregulated hyperactivity. We therefore tested three anti-seizure medications (ASMs), phenytoin, perampanel, and carbamazepine, on NGN2 neurons from day 21 of differentiation in this system. The key finding was that, while all compounds altered spontaneous firing, carbamazepine 200 µ M significantly improved gameplay metrics. This marks the first demonstration of altered SBI following exogenous drug treatment. Notably, only inhibitory compounds enhanced goal-directed activity, linking glutamatergic attenuation to performance. Neurocomputational analysis revealed nuanced pharmacological responses during closed-loop stimulation, highlighting insights beyond spontaneous activity metrics.